The DUAL study VII compared the use of basal-bolus insulin versus IDegLira, showing the non-inferiority of the latter in declining HbA1c, with a lower risk of hypoglycemia and significant weight loss in contrast to weight gain in the basal-bolus group. The gene discussed is INS; the disease is Hypoglycemia.